Cover Image

Not for Sale



View/Hide Left Panel

Hemophilus influenzae type B, 245248

hepatitis A virus, 258

hepatitis B virus, 272276

herpes simplex viruses, 301310

Herpesvirus varicellae vaccine, 334339

influenza viruses, 358362

Neisseria gonorrhoeae, 378382

parainfluenza viruses, 393395

pertussis, 180181

respiratory syncytial virus, 405407

rotavirus, 420421

streptococcus group B, 434437

Cost per dose, 66, 141, 144

Cost-effectiveness analysis, 22, 2425, 149, 150

Cost-utility analysis, 22

Cytomegalovirus (CMV)

anticipated vaccine utilization, 226227

control suitability, 218219

cost of illness, 227232

disease burden, 199215

disease description, 198

host immune response, 199

pathogen description, 199

total disease burden values, 215

vaccine development prospects, 224226

vaccine preventable illness, 219224

vaccine target populations, 215, 218

D

Decision analysis, 21, 24, 149

Delay of benefits, 11, 101

Delivery requirements, 66

Delphi method, 25

Development costs, 64

Direct costs, 50, 5254, 92

Discounting, 11, 30, 100103, 135137

Disease burden

coccidioidomycosis, 185188

conclusions on, 57

cytomegalovirus, 199215

equity issues, 121

findings on, 54

Hemophilus influenzae type B, 236240

hepatitis A virus, 253255

hepatitis B virus, 263266

herpes simplex viruses, 281294

Herpesvirus varicellae, 315323

influenza viruses, 344351

limitations of, 4849, 54, 57

multiple profile approach, 122

Neisseria gonorrhoeae, 370373

parainfluenza viruses, 386388

pertussis, 174, 175

recommendations for, 57

respiratory syncytial virus, 398400

rotavirus, 412417

streptococcus group B, 425430

system elements, 6, 3949

trend factors, 96

value judgments and, 4950

Disease burden costs

calculation of, 1213, 50, 5254

coccidioidomycosis, 194

cytomegalovirus, 227232

Hemophilus influenzae type B, 245247

hepatitis A virus, 258259

hepatitis B virus, 272274

herpes simplex viruses, 301306

Herpesvirus varicellae, 334339

influenza viruses, 359360

Neisseria gonorrhoeae, 378380

parainfluenza viruses, 393394

respiratory syncytial virus, 406

rotavirus, 420421

streptococcus group B, 434435

Dominance rule, 1415, 34, 128

E

Efficacy, 65

Entamoeba histolytica, 157158

Epstein-Barr virus (EBV), 158

Equity issues, 121

Escherichia coli, 158159

Expected annual health benefits, 94, 110

Expert judgments, 25, 75

G

Giardia lamblia, 159

Gonorrhea. See Neisseria gonorrhoeae

Gram-negative bacteria, 159

H

Health belief model (HBM), 6971, 74, 75, 83, 89.

See also Anticipated vaccine utilization

Health benefits and costs

analytical methods, 2934

assumptions and explanations, 95109

calculation of, 11, 9295

equity issues, 121

ranking and, 3437

results of analysis, 110120

See also Vaccine preventable illness;

Vaccine preventable illness costs



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement